Participants who diagnosed with unruptured ectopic pregnancy. Unruptured ectopic pregnancy, Letrozole, Methotrexate
Conditions
Interventions
Participants will be randomly allocated using block randomization, Those assigned to the study group receive Letrozel 10 mg per day orally for 10 days.,The participants in this group will be treated
Experimental Drug,Active Comparator Drug
Letrozle group,Methotrexate group
Sponsors
Buri Ram Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Female patients aged 18 - 40 years. 2. Clinically diagnosed with unruptured ectopic pregnancy confirmed by ultrasound. 3. Hemodynamically stable. 3 Serum hCG levels between 1,000 and 3,000 IU/L. 4. No evidence of intrauterine pregnancy or fetal heartbeat on ultrasound.
Exclusion criteria
Exclusion criteria: 1. Evidence of ruptured ectopic pregnancy or hemodynamic instability. 2. Serum hCG > 3,000 IU/L. 3. Known contraindications to letrozole or methotrexate. 4. Severe hepatic or renal dysfunction. 5. Presence of other significant medical conditions that may interfere with treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sucess of medical treatment At 8 weeks after end of the intervention. Blood HCG less than 5 IU/L | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to resolution HCG 8 weeks Mean,Adverse events: leukopenia, hepatitis, ulcerative stomatitis, nausea, abdominal distress ect Three months after treatment Number | — |
Countries
Thailand
Contacts
Public ContactSiriphen Uengphinitphong
Buri Ram
Outcome results
None listed